Skip to main content

Biodesix Inc

BDSX
Exchange
Nasdaq
Industry
Services-Medical Laboratories
SEC CIK
0001439725

In the last 90 days, Biodesix Inc insiders filed 2 open-market purchases and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.

Key figures

Insider buysLast 90 days, $1.03M in total
2
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +5 vs. previous quarter
45
13F valueReported value at the end of Q2 2026
$98.5M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding BDSX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BDSX at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Biodesix Inc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 13, 2026 (view filing)5:22 PM ETAug 121 daySchuler Jack W10% Owner, Other: Emeritus DirectorPPurchase+15.0K$24.47+$367.0K+2.8%555.8K after
Aug 12, 2026 (view filing)5:55 PM ETAug 10-112 daysSchuler Jack W10% Owner, Other: Emeritus DirectorPPurchase+27.6K$24.13+$665.9K+5.4%540.8K after2 lots
Feb 23, 2026 (view filing)Feb 23Same dayVazquez ChrisChief Accounting OfficerSSale−211$12.78−$2.70K−11.7%1.59K after
Feb 23, 2026 (view filing)Feb 23Same dayCowie Robin HarperCFO, Sec'y & TreasurerSSale−535$12.78−$6.84K−3.2%16.2K after
Feb 23, 2026 (view filing)Feb 23Same dayHutton ScottPresident & CEOSSale−1.49K$12.78−$19.0K−3.0%48.8K after
Feb 23, 2026 (view filing)Feb 23Same dayPestano Gary AnthonyChief Development OfficerSSale−556$12.78−$7.11K−5.1%10.4K after
Feb 23, 2026 (view filing)Feb 23Same dayO'Kane KieranChief Commercial OfficerSSale−535$12.78−$6.84K−5.2%9.82K after
Feb 11, 2026 (view filing)Feb 101 dayCowie Robin HarperCFO, Sec'y & TreasurerSSale−941$10.08−$9.49K−5.8%15.3K after
Feb 11, 2026 (view filing)Feb 101 dayVazquez ChrisChief Accounting OfficerSSale−101$10.08−$1.02K−7.6%1.23K after
Feb 11, 2026 (view filing)Feb 101 dayO'Kane KieranChief Commercial OfficerSSale−584$10.08−$5.89K−6.2%8.88K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Biodesix Inc at the end of Q2 2026; share changes are against Q1 2026.

See all 45 holders
Institutions holding BDSX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
AIGH Capital Management LLC678,328$15.3M1.38%−80,000−10.5%Reduced
Soleus Capital Management, L.P.585,958$13.2M0.46%+169,359+40.7%Added
Telemark Asset Management, LLC489,824$11.0M0.80%00.0%Unchanged
Standard Life Aberdeen plc388,639$8.76M0.01%−69,799−15.2%Reduced
Birchview Capital, LP286,804$6.47M3.02%00.0%Unchanged
Vanguard Capital Management LLC284,169$6.41M0.00%+29,008+11.4%Added
Essex Investment Management Co LLC241,915$5.46M0.71%+109,829+83.1%Added
Opaleye Management Inc.180,000$4.06M0.37%−58,047−24.4%Reduced
Marshall Wace, LLP116,199$2.62M0.00%−25,437−18.0%Reduced
Perceptive Advisors LLC108,694$2.45M0.04%+108,694New